Victory Capital Management Inc Exelixis, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

A detailed history of Victory Capital Management Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 136,178 shares of EXEL stock, worth $4.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

136,178

Previous 116,806 16.58%

Holding current value

$4.89 Million

Previous $2.62 Million 34.64%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$21.96 - $27.6 $425,409 - $534,667	19,372 Added 16.58%	136,178 $3.53 Million
Q2 2024 Aug 05, 2024	BUY	$20.34 - $23.73 $312,585 - $364,682	15,368 Added 15.15%	116,806 $2.62 Million
Q1 2024 May 03, 2024	SELL	$20.17 - $23.93 $590,839 - $700,981	-29,293 Reduced 22.41%	101,438 $2.41 Million
Q4 2023 Feb 05, 2024	BUY	$19.25 - $24.13 $1.43 Million - $1.8 Million	74,410 Added 132.12%	130,731 $3.14 Million
Q3 2023 Nov 06, 2023	BUY	$19.04 - $22.74 $17,650 - $21,079	927 Added 1.67%	56,321 $1.23 Million
Q2 2023 Jul 27, 2023	SELL	$18.17 - $20.48 $345 - $389	-19 Reduced 0.03%	55,394 $1.06 Million
Q1 2023 May 02, 2023	SELL	$16.3 - $19.41 $341,566 - $406,736	-20,955 Reduced 27.44%	55,413 $1.08 Million
Q4 2022 Feb 10, 2023	BUY	$14.96 - $17.39 $30,024 - $34,901	2,007 Added 2.7%	76,368 $1.22 Million
Q4 2022 Feb 09, 2023	SELL	$14.96 - $17.39 $585,953 - $681,131	-39,168 Reduced 34.5%	74,361 $1.19 Million
Q3 2022 Nov 02, 2022	SELL	$15.68 - $22.27 $3,449 - $4,899	-220 Reduced 0.19%	113,529 $1.78 Million
Q2 2022 Aug 01, 2022	SELL	$17.44 - $23.16 $7,848 - $10,422	-450 Reduced 0.39%	113,749 $2.37 Million
Q1 2022 May 04, 2022	BUY	$17.03 - $22.67 $867,150 - $1.15 Million	50,919 Added 80.47%	114,199 $2.55 Million
Q4 2021 Feb 07, 2022	BUY	$15.84 - $21.88 $95,832 - $132,374	6,050 Added 10.57%	63,280 $1.16 Million
Q3 2021 Nov 02, 2021	SELL	$16.3 - $21.14 $357,866 - $464,128	-21,955 Reduced 27.73%	57,230 $1.21 Million
Q2 2021 Aug 03, 2021	SELL	$17.95 - $25.56 $396,533 - $564,645	-22,091 Reduced 21.81%	79,185 $1.44 Million
Q1 2021 May 04, 2021	SELL	$20.53 - $25.22 $2.19 Million - $2.69 Million	-106,670 Reduced 51.3%	101,276 $2.29 Million
Q4 2020 Feb 01, 2021	SELL	$18.39 - $24.8 $530,661 - $715,628	-28,856 Reduced 12.19%	207,946 $4.17 Million
Q3 2020 Nov 09, 2020	BUY	$20.67 - $26.94 $2 Million - $2.6 Million	96,549 Added 68.84%	236,802 $5.79 Million
Q2 2020 Aug 07, 2020	BUY	$16.46 - $27.42 $8,443 - $14,066	513 Added 0.37%	140,253 $3.33 Million
Q1 2020 May 04, 2020	SELL	$14.46 - $21.8 $1.17 Million - $1.76 Million	-80,861 Reduced 36.65%	139,740 $2.41 Million
Q4 2019 Feb 06, 2020	BUY	$15.15 - $18.89 $693,460 - $864,651	45,773 Added 26.18%	220,601 $3.89 Million
Q4 2019 Feb 04, 2020	SELL	$15.15 - $18.89 $293,228 - $365,615	-19,355 Reduced 9.97%	174,828 $3.01 Million
Q3 2019 Nov 12, 2019	BUY	$17.68 - $22.65 $2.07 Million - $2.66 Million	117,355 Added 152.75%	194,183 $3.43 Million
Q2 2019 Aug 15, 2019	BUY	$18.93 - $24.75 $3,218 - $4,207	170 Added 0.22%	76,828 $1.64 Million
Q1 2019 May 03, 2019	SELL	$19.6 - $24.76 $324,615 - $410,075	-16,562 Reduced 17.77%	76,658 $1.82 Million
Q4 2018 Feb 05, 2019	SELL	$13.65 - $21.8 $4,681 - $7,477	-343 Reduced 0.37%	93,220 $1.83 Million
Q3 2018 Nov 01, 2018	BUY	$15.87 - $22.4 $553,878 - $781,782	34,901 Added 59.5%	93,563 $1.66 Million
Q2 2018 Aug 02, 2018	BUY	$18.56 - $22.45 $127,599 - $154,343	6,875 Added 13.28%	58,662 $1.26 Million
Q1 2018 May 04, 2018	BUY	$22.15 - $31.89 $1.15 Million - $1.65 Million	51,787 New	51,787 $1.15 Million

Others Institutions Holding EXEL

# of Institutions

503

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Exelixis, Inc. Transaction History